Skin Diseases  >>  Halaven (eribulin mesylate)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT01432886: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Checkmark In combination withEribulin mesylate for adv/recurrent HER2+ve BC
Sep 2014 - Sep 2014: In combination withEribulin mesylate for adv/recurrent HER2+ve BC
Completed
1
12
Japan
E7389
Eisai Co., Ltd.
Breast Cancer
08/13
12/13
NCT02014337: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Completed
1
37
US
Mifepristone and Eribulin in combination, Korlym®, Halaven
Corcept Therapeutics
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
12/17
12/17
NCT01837095: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Completed
1
54
US, Europe
POL6326
Polyphor Ltd.
Metastatic Breast Cancer
08/18
08/18

Download Options